# EDGAR Filing Document

**Accession Number:** 0001812364
**File Stem:** 0001193125-25-139146
**Filing Date:** 2025-6
**Character Count:** 13846
**Document Hash:** e4edee34dbe1f8798987ffe1f55dc3c4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-139146.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001193125-25-139146

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250608

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Relay Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001812364
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39385
- **FILM NUMBER:** 251040144

**BUSINESS ADDRESS:**
- **STREET 1:** 60 HAMPSHIRE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-370-8837

**MAIL ADDRESS:**
- **STREET 1:** 60 HAMPSHIRE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 11, 2025 (June 8, 2025)

## RELAY THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39385** | **47-3923475** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **60 Hampshire Street** |  |
| **Cambridge, Massachusetts** | **02139** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (617) 370-8837

#### (Former Address: 399 Binney Street, Cambridge, Massachusetts 02142)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange on<br>which registered** |
| Common Stock, par value $0.0001 per share | RLAY | Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02.** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**  |

---

*Resignation of Jami Ruben as a Class III Director* 

On June 8, 2025, Jami Ruben informed the Board of Directors (the "Board") of Relay Therapeutics, Inc. (the "Company") that she is resigning as a member of the Board and as a member of Audit Committee of the Board (the "Audit Committee"), effective immediately. Ms. Rubin's resignation is not the result of any dispute or disagreement with the Company.

*Appointment of Claire Mazumdar, Ph. D., MBA as a Class III Director* 

On June 9, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Claire Mazumdar, Ph. D., MBA as a member of the Board, effective as of June 9, 2025. The Board determined that Dr. Mazumdar is independent under the listing standards of Nasdaq and the Company's corporate governance guidelines. Dr. Mazumdar will serve as a Class III director with a term expiring at the annual meeting of stockholders to be held in 2026. Dr. Mazumdar will also serve as the chair of the Audit Committee, as of June 9, 2025.

As a non-employee director, Dr. Mazumdar will receive cash compensation and equity awards for her Board service in accordance with the Company's amended and restated non-employee director compensation policy. In connection with her appointment, Dr. Mazumdar received an initial option to purchase up to 421,241 shares of the Company's common stock, par value $0.001 per share, with an exercise price per share of $3.36, the closing price of the Common Stock on the Nasdaq Global Market on June 9, 2025, vesting in equal monthly installments over thirty six months.

Dr. Mazumdar is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Dr. Mazumdar and any other persons pursuant to which she was selected as a director. In addition, Dr. Mazumdar will enter into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors.

The Company issued a press release on June 11, 2025 announcing the appointment of Dr. Mazumdar to the Board. A copy of this press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 99.1 | [Press Release issued by Relay Therapeutics, Inc. on June 11, 2025.](d948938dex991.htm) |
| 104 | Cover page interactive data file (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 11, 2025 | **Relay Therapeutics, Inc.** | **Relay Therapeutics, Inc.** |
|  | By: | /s/ Brian Adams |
|  |  | Brian Adams |
|  |  | Chief Legal Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g948938g0611232200964.jpg)

**Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors** 

Cambridge, Mass. – June 11, 2025 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025.

"It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

Dr. Mazumdar is the founding Chief Executive Officer of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company. Prior to Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the precision medicine company's global partnership with Roche Pharmaceuticals. Earlier in her career, she held a position at Third Rock Ventures, where she focused on company formation and business development. She holds a B.S. in biological engineering from the Massachusetts Institute of Technology, and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine.

**About Relay Therapeutics** 

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its Dynamo<sup>®</sup> platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

**Cautionary Note Regarding Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Relay Therapeutics' strategy, business plans and focus; the progress and timing of the clinical development of the programs across Relay Therapeutics' portfolio; the expected therapeutic benefits and potential efficacy and tolerability of RLY-2608, both as a monotherapy and in combination with other agents, and its other programs, as well as the clinical data for RLY-2608; the interactions with regulatory authorities and any related approvals; the potential market opportunity for RLY-2608; the cash runway projection; the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; and the expectations regarding Relay Therapeutics' use of capital and expenses. The words "may," "might," "will," "could," "would," "should," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

------

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: Relay Therapeutics' restructuring activities may be more costly or time-consuming than we expect or may not achieve their intended results; the timing, execution, and expected impact of Relay Therapeutics' restructuring plans (including the scope and timing of workforce reductions); the expected decrease in annual spending; the expected sufficiency of Relay Therapeutics' existing cash resources; the internal and external costs required for Relay Therapeutics' ongoing and planned activities, and the resulting impact on expense and use of cash, may be higher than expected, which may cause the company to use cash more quickly than expected or to change or curtail some of Relay Therapeutics' plans or both; the impact of global economic uncertainty, geopolitical instability and conflicts, or public health epidemics or outbreaks of an infectious disease on countries or regions in which Relay Therapeutics has operations or does business, as well as on the timing and anticipated results of its clinical trials, strategy, future operations and profitability; significant political, trade, or regulatory developments, such as tariffs, beyond Relay Therapeutics' control; the delay or pause of any current or planned clinical trials or the development of Relay Therapeutics' drug candidates; the risk that the preliminary or interim results of its preclinical or clinical trials may not be predictive of future or final results in connection with future clinical trials of its product candidates and that interim and early clinical data may change as more patient data become available and are subject to audit and verification procedures; Relay Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of its planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Relay Therapeutics' most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Relay Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Relay Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

**Contact:** 

Pete Rahmer

prahmer@relaytx.com

**Media:** 

Dan Budwick

1AB

973-271-6085

dan@1abmedia.com